(Q45231619)

11 December 2017

title

Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides (English)

1 reference

11 December 2017

4

1 reference

11 December 2017

6

Bernard Roques

1 reference

11 December 2017

2

Bruno Hurtrel

1 reference

11 December 2017

5

Valérie Monceaux

1 reference

11 December 2017

Guillaume Belliard

1

1 reference

11 December 2017

Emmanuel Moreau

3

1 reference

11 December 2017

Claude Desgranges

7

1 reference

11 December 2017

Anne-Marie Aubertin

8

1 reference

11 December 2017

Roger Le Grand

9

1 reference

11 December 2017

Sylviane Muller

10

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

11 December 2017

1 reference

11 December 2017

volume

23

1 reference

11 December 2017

issue

11

1 reference

11 December 2017

page(s)

1399-1407

1 reference

HIV-1 Tat protein as a potential AIDS vaccine

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Tat as a transcriptional activator and a potential therapeutic target for HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

From the outside in: extracellular activities of HIV Tat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Quantifying the uncertainty in forecasts of anthropogenic climate change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Evaluation in Rhesus Macaques of Tat and Rev-Targeted Immunization as a Preventive Vaccine against Mucosal Challenge with SHIV-BX08

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

The human uniqueness of HIV: innate immunity and the viral Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Tat-neutralizing antibodies in vaccinated macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat, and vpu genes from HIV-1 Lai

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

HIV-1 Tat-based vaccines: from basic science to clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.037

10.1016/J.VACCINE.2004.08.037

7 January 2021

Identifiers

DOI

1 reference

11 December 2017

1 reference